ICC Advance Access originally published online on May 29, 2009
Industrial and Corporate Change 2009 18(5):869-899; doi:10.1093/icc/dtp028
| ||||||||||||||||||||||||||||||||||||||||||||||||
Inter-firm reverse technology transfer: the home country effect of R&D internationalization
Correspondence: Paola Criscuolo, Imperial College Business School, Imperial College London, South Kensington Campus, London SW7 2AZ, UK. e-mail: p.criscuolo{at}imperial.ac.uk
One consequence of the internationalization of R&D may be the transfer of foreign technology from the multinational to other firms in its home country. This phenomenon, which can be termed inter-firm reverse technology transfer and which has not been directly analyzed by either the international management or foreign direct investment literature, may have significant implications for policy—particularly in Europe. This article is a first attempt in this direction. Patent citation analysis on a database of EPO patents granted to 17 European chemical and pharmaceutical multinationals over the period 1985–2005 shows that they act as a channel for the transmission of knowledge developed in the United States, to other home country firms; these results are robust to the exclusion of examiner citations. We find that this technology transfer process is explained by the degree of home country embeddedness of the multinational firm, the US subsidiaries’ engagement in asset-augmenting activities, and the presence of a technology gap between the United States and the home country. These results point to an alternative understanding of foreign direct R&D investment and its implications for the home country's technological activity and general competitive performance.